Literature DB >> 7745420

Interferon-alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy.

M Sabatelli, T Mignogna, G Lippi, M Milone, V Di Lazzaro, P Tonali, E Bertini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7745420      PMCID： PMC1073503          DOI： 10.1136/jnnp.58.5.638

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  3 in total

Review 1.  [Interferon alpha and autoimmunity].

Authors:  T Papo; J C Piette; L T Du; P Godeau
Journal:  Ann Med Interne (Paris)       Date:  1993

Review 2.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy.

Authors:  P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

3.  Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

Authors:  L Durelli; M R Bongioanni; R Cavallo; B Ferrero; R Ferri; M F Ferrio; G B Bradac; A Riva; S Vai; M Geuna
Journal:  Neurology       Date:  1994-03       Impact factor: 9.910
  3 in total
  8 in total

1.  Chronic Inflammatory Demyelinating Polyneuropathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-07       Impact factor: 3.598

Review 2.  Current concepts and controversy in chronic inflammatory demyelinating polyneuropathy.

Authors:  David S Saperstein; Richard J Barohn
Journal:  Curr Neurol Neurosci Rep       Date:  2003-01       Impact factor: 5.081

3.  Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy.

Authors:  Giovanni Pavesi; Luigi Cattaneo; Adriana Marbini; Franco Gemignani; Domenico Mancia
Journal:  J Neurol       Date:  2002-06       Impact factor: 4.849

4.  Chronic motor neuropathies: response to interferon-beta1a after failure of conventional therapies.

Authors:  I S Martina; P A van Doorn; P I Schmitz; J Meulstee; F G van der Meché
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-02       Impact factor: 10.154

Review 5.  Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Krista Kuitwaard; Pieter A van Doorn
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

6.  Chronic inflammatory demyelinating polyneuropathy.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

Review 7.  Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside.

Authors:  Amanda C Peltier; Peter D Donofrio
Journal:  Semin Neurol       Date:  2012-11-01       Impact factor: 3.420

Review 8.  Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variants.

Authors:  Mazen M Dimachkie; Richard J Barohn; Jonathan Katz
Journal:  Neurol Clin       Date:  2013-02-16       Impact factor: 3.806
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.